<DOC>
	<DOCNO>NCT02713880</DOCNO>
	<brief_summary>Development new MS-based biomarker early sensitive diagnosis Transthyretin-Related Familial Amyloidotic Polyneuropathy plasma . Testing clinical robustness , specificity long-term stability biomarker .</brief_summary>
	<brief_title>Biomarker Patients With Transthyretin-Related Familial Amyloidotic Polyneuropathy</brief_title>
	<detailed_description>Diseases diverse etiology correlate term `` polyneuropathy '' ( PNP ) . The pathogenesis may inflammatory , autoimmune , metabolic , toxic hereditary nature . Careful clinical electrodiagnostic assessment , attention pattern involvement type nerve fiber affect , narrow differential diagnosis help focus laboratory evaluation . Beside frequent genetic etiology PNP ( pmp22 , MFN2 ) one cause polyneuropathy may hereditary amyloidosis . This term describe accumulation misfolded protein interstitial space . The abnormal accumulation β-fibrils detect histologically Congo pink stain . Aside acquire amyloidotic neuropathy ( e.g . PNP cause AL-amyloidosis also hereditary amyloidotic neuropathy . These described endemic Sweden , Portugal Japan . More recent study provide evidence presence hereditary amyloidotic neuropathy amongst German population currently underdiagnosed . The common form hereditary familial amyloidotic neuropathy ( FAP ) Transthyretin-related FAP , however two amyloidogenic protein describe : Apolipoprotein A-I Gelsolin . The TTR-FAP autosomal dominant disease , exact prevalence unknown estimate around 1:100,000 1:1,000,000 normal population . By limit study population patient PNP unknown etiology possible gain evidence prevalence disease Germany investigate few patient . While diagnosis amyloidotic neuropathy conduct histologically , molecular genetic approach necessary diagnose TTR-FAP . Even though 100 point mutation know cause disease , common amino acid change V30M . The mutation TTR gene cause destabilization physiologically tetrameric protein . Usually transthyretin consist four identical monomeric subunit bind thyroxin circulate blood plasma . The monomeric subunit exhibit pronounce β-sheet structure lead accumulation unsoluble β-fibrils destabilise TTR-FAP . This accumulation misfolded TTR lead three phenotype know - cardiac TTR amyloidosis , - leptomeningeal TTR amyloidosis - TTR-FAP . The TTR-FAP heterogeneous phenotype manifest start age 18 may lead death within 10 year . The symptom categorize three group : Dysfunction peripheral nerve : - Dissociated anesthesia - Muscle paresis atrophy - Dysaesthesia paraesthesia - Reduced skin temperature - Coldness - Hoarseness Autonomic dysfunction : - Dysuria - Diarrhea - Constipation - Orthostatic dysregulation - Erectile dysfunction - Nausea Constitutional condition - Anemia - Weight loss - Arrhythmia - Edema - Acroparaesthesia The currently available therapeutic approach either liver transplantation ( liver mainly produce transthyretin feasible approach ) recently also TTR-tetramer stabilize agent ( Tafamidis ) . Tafamidis ( Vyndaqel® ) gain European approval `` exceptional circumstance '' November 2011 treat FAP adult symptomatic polyneuropathy.In light potential therapy rare disease study aim determine prevalence TTR-FAP select , clinical subpopulation . New method , like mass-spectrometry give good chance characterize specific metabolic alteration blood ( plasma ) affect patient allow diagnose future disease earlier , high sensitivity specificity . Therefore goal study identify validate new biochemical marker plasma affect patient help benefit patient early diagnose thereby earlier treatment .</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Amyloid Neuropathies</mesh_term>
	<mesh_term>Amyloidosis , Familial</mesh_term>
	<criteria>Informed consent obtain parent study related procedure . Patients gender older 2 month The patient diagnosis TransthyretinRelated Familial Amyloidotic Polyneuropathy highgrade suspicion TransthyretinRelated Familial Amyloidotic Polyneuropathy Highgrade suspicion present , one inclusion criterion valid : Positive family anamnesis TransthyretinRelated Familial Amyloidotic Polyneuropathy Orthostatic dysregulation Acroparaesthesia Dysaesthesia paraesthesia Muscle paresis atrophy No Informed consent parent study related procedure . Patients gender younger 2 month No diagnosis TransthyretinRelated Familial Amyloidotic Polyneuropathy valid criterion profound suspicion TransthyretinRelated Familial Amyloidotic Polyneuropathy</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Peripheral Nervous System Diseases</keyword>
	<keyword>Neuromuscular Diseases</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
</DOC>